- Home
- CRNT vs CRDF Comparison
CRNT vs CRDF Comparison
Compare CRNT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNT | CRDF |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 142.1M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRNT | CRDF |
|---|---|---|
| Price | $2.05 | $2.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $5.50 | ★ $10.63 |
| AVG Volume (30 Days) | 480.2K | ★ 862.7K |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $363,330,000.00 | $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.06 | N/A |
| P/E Ratio | $134.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.82 | $1.90 |
| 52 Week High | $5.73 | $5.64 |
Technical Indicators
Market Signals| Indicator | CRNT | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 58.01 |
| Support Level | $1.93 | $2.09 |
| Resistance Level | $2.16 | $2.59 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 50.00 | 63.72 |
Price Performance
Historical ComparisonAbout CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.